Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01646112 · ClinicalTrials.gov registry record

Uncertain Genetic Test Results for Lynch Syndrome

A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
27
Enrollment target

NCT01646112: Completed study, sponsored by National Human Genome Research Institute (NHGRI).

NCT01646112 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01646112 has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
27 participants
Enrollment target

Study Summary

Background: * Individuals have varying tolerances for receiving ambiguous information. However, not much is known about how ambiguous genetic testing information is received. Also, not much is known about how at-risk individuals internalize and process these results. More information is needed about how this information affects a person s life. * Lynch Syndrome is a genetic condition that carries a high risk of colon cancer and other cancers. Individuals at risk for Lynch Syndrome can have genetic testing for it. The test may confirm a diagnosis and determine actions that can be taken. Results from genetic testing can also affect the perspectives of relatives who might also be affected. However, genetic testing can also produce variants of unknown significance (VUS). VUS are data that may not provide enough information to make decisions. Researchers want to study people who have received a VUS result for genetic testing for Lynch Syndrome. Objectives: \- To learn more about the impact and experience of receiving a VUS for Lynch Syndrome genetic testing. Eligibility: \- Individuals at least 18 years of age who have recently had a VUS result on a genetic test for Lynch Syndrome. Design: * Participants will be asked to answer demographic questions. They will also have a 45- to 60-minute phone interview. * During the phone interview, participants will be asked a series of questions about their diagnosis. They will be asked about how they received the result and how they felt right after receiving it. They will also discuss who they have spoken to about the result.

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2012-04-25
Est. Completion 2016-02-05

What the finished NCT01646112 record still lists

NCT01646112 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01646112 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01646112 about?

NCT01646112 is a clinical study titled "Uncertain Genetic Test Results for Lynch Syndrome". Background: * Individuals have varying tolerances for receiving ambiguous information. However, not much is known about how ambiguous genetic testing information is received. Also, not much is known about how at-risk individuals internalize and process these results. More information is needed abou...

What is the current status of trial NCT01646112?

This trial is currently completed. The enrollment target is 27 participants. The study started on 2012-04-25. Estimated completion is 2016-02-05.

Who is sponsoring clinical trial NCT01646112?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01646112, the US trial registry maintained by the National Library of Medicine. NCT01646112 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.